Loading…
Tvardi Therapeutics, Inc. is projected to decline to $2.98 by 2027, a -9% move from its current price of $3.28. TVRD is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $2.89 | $3.28 | $3.71 | -0.06% |
| Jul 14 | $2.75 | $3.28 | $3.91 | -0.13% |
| Jul 15 | $2.64 | $3.27 | $4.06 | -0.19% |
| Jul 16 | $2.55 | $3.27 | $4.20 | -0.25% |
| Jul 17 | $2.48 | $3.27 | $4.32 | -0.32% |
| Jul 18 | $2.41 | $3.27 | $4.43 | -0.38% |
| Jul 19 | $2.35 | $3.27 | $4.54 | -0.44% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.35 | $3.27 | $4.54 | -0.44% |
| Week 2 | $2.04 | $3.25 | $5.18 | -0.89% |
| Week 3 | $1.83 | $3.24 | $5.73 | -1.33% |
| Week 4 | $1.67 | $3.22 | $6.23 | -1.77% |
| Week 5 | $1.54 | $3.21 | $6.70 | -2.20% |
| Week 6 | $1.43 | $3.19 | $7.16 | -2.64% |
| Week 7 | $1.33 | $3.18 | $7.60 | -3.07% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing oral, small molecule therapies that target signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States.
Its lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage.
Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.
Tvardi Therapeutics, Inc. (TVRD) operates in the Healthcare sector. The stock is currently priced at $3.28 with a market capitalization of $30.77M and a rank of 4764.
The company focuses on developing STAT3 inhibitors for inflammatory and proliferative diseases. These products include TTI-101 and TTI-109, with TTI-101 in Phase 1b/2 for IPF and HCC and TTI-109 in Phase-1.
Forecasts show a path to higher prices over the longer term, with 2030 average price of $4.35, 2040 average of $7.44, and 2050 average of $17.34. Corresponding ROI figures are 32.5% for 2030, 126.7% for 2040, and 428.6% for 2050, with sentiment labeled as BULLISH for these years. Near-term forecasts for 2026–2029 indicate more modest or neutral expectations, with 2026 average $3.28, 2027 $2.98, 2028 $3.29, and 2029 $3.21.
A major floor 54.3% below — a decisive break under it would weaken the trend.
The nearest floor, 54.3% below — buyers have tended to step in here.
The nearest ceiling, 52.4% above — a clean break opens room to run.
A major ceiling 106.1% above — clearing it would confirm fresh momentum.
Key TVRD support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of TVRD market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.44 | Sell | $3.38 | Sell |
| MA 10 | $2.65 | Buy | $3.03 | Buy |
| MA 20 | $2.61 | Buy | $2.85 | Buy |
| MA 50 | $3.13 | Buy | $3.01 | Buy |
| MA 100 | $3.30 | Sell | $3.88 | Sell |
| MA 200 | $6.26 | Sell | $7.03 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 54.09 | Neutral |
| Stoch RSI (14) | 62.37 | Neutral |
| CCI (20) | 88.49 | Neutral |
| Williams %R (14) | -49.14 | Info |
| MACD (12,26,9) | 0.23 | Buy |
| ROC (12) | 35.54 | Buy |
| Bollinger %B (20,2) | 0.72 | Neutral |
| Stochastic %K (14) | 50.86 | Neutral |
| TRIX (15) | -0.81 | Sell |
| Awesome (5,34) | 0.60 | Buy |
| Ultimate (7,14,28) | 59.48 | Neutral |
| Momentum (10) | 0.92 | Buy |
| Aroon Osc (25) | 28.00 | Buy |
| Hull MA (9) | 4.43 | Sell |
| ADX (14) | 31.03 | Buy |
| ATR (14) | 0.40 | Info |
The 30-day technical picture is BULLISH. RSI14 is 50, suggesting neutral momentum around the midline. The stock trades around the SMA50 of $3.13 and remains below the SMA200 of $6.26, implying near-term upside potential if momentum strengthens. The 30-day range spans from $1.44 to $7.45, with support at $1.50 and resistance at $5.00.
These dynamics occur in the context of an annualized volatility of 200%, underscoring the likelihood of sharp moves in the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.50 | $3.28 | $4.26 | 0% | Neutral | |
| $2.16 | $2.98 | $4.44 | -9% | Neutral | |
| $2.24 | $3.29 | $5.22 | 0% | Neutral | |
| $2.08 | $3.21 | $5.35 | -2% | Neutral | |
| $2.69 | $4.35 | $7.54 | +32% | Bullish | |
| $3.43 | $5.80 | $10.42 | +77% | Bullish | |
| $2.88 | $5.07 | $9.40 | +55% | Bullish | |
| $2.61 | $4.79 | $9.12 | +46% | Bullish | |
| $2.64 | $5.04 | $9.85 | +54% | Bullish | |
| $2.41 | $4.79 | $9.56 | +46% | Bullish | |
| $3.35 | $7.44 | $16.32 | +127% | Bullish | |
| $7.80 | $17.34 | $39.88 | +429% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.50 | $3.28 | $4.09 | +0.00% |
| August 2026 | $2.63 | $3.19 | $4.02 | -2.88% |
| September 2026 | $2.52 | $3.09 | $3.99 | -2.85% |
| October 2026 | $2.62 | $3.26 | $4.27 | +5.38% |
| November 2026 | $2.62 | $3.29 | $4.37 | +0.88% |
| December 2026 | $2.49 | $3.16 | $4.26 | -3.91% |
Click any year to see its month-by-month TVRD forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Tvardi Therapeutics, Inc.'s 2026 outlook centres on $3.28, within a $1.50 to $4.26 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, TVRD could reach as high as $4.44, with a base case around $2.98 and support toward $2.16 — roughly -9% from $3.28. Price action looks broadly range-bound.
Expect TVRD to range from $2.24 to $5.22 through 2028. The $3.29 average target implies a 0% move from current prices. That is up +10% on the projected 2027 average. A consolidation phase looks the most probable path here.
The TVRD price prediction for 2029 points to an average of $3.21 (low $2.08, high $5.35) — a potential decline of -2% on today's $3.28. Price action looks broadly range-bound.
In 2030, TVRD is projected to trade between $2.69 and $7.54, averaging $4.35 — a potential gain of +32% from today's $3.28. That is up +35% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Tvardi Therapeutics, Inc.'s 2031 outlook centres on $5.80, within a $3.43 to $10.42 range. That is up +33% on the projected 2030 average. That marks a +77% change versus current levels. Momentum favours further upside here.
By 2032, TVRD could reach as high as $9.40, with a base case around $5.07 and support toward $2.88 — roughly +55% from $3.28. Buyers look set to stay in control over this stretch.
Expect TVRD to range from $2.61 to $9.12 through 2033. The $4.79 average target implies a +46% move from current prices. That is -6% versus the projected 2032 average. Momentum favours further upside here.
The TVRD price prediction for 2034 points to an average of $5.04 (low $2.64, high $9.85) — a potential gain of +54% on today's $3.28. Buyers look set to stay in control over this stretch.
In 2035, TVRD is projected to trade between $2.41 and $9.56, averaging $4.79 — a potential gain of +46% from today's $3.28. That is -5% versus the projected 2034 average. Momentum favours further upside here.
Tvardi Therapeutics, Inc.'s 2040 outlook centres on $7.44, within a $3.35 to $16.32 range. That is up +55% on the projected 2035 average. That marks a +127% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, TVRD could reach as high as $39.88, with a base case around $17.34 and support toward $7.80 — roughly +429% from $3.28. Momentum favours further upside here.
Investing $1,000 in TVRD today (≈ 304.878049 TVRD) could be worth
$5,286.13
+$4,286.13 (+429%) by 2050 · US Dollar
Based on the average projected TVRD price of $17.34 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in TVRDwould be worth at today's price.
$1,000 invested in TVRD on Jul 10, 2025 (≈ 44.11116 TVRD) would be worth
$144.68
-$855.32 (-85.5%) today · 0.14× · US Dollar
Based on a TVRD entry price of $22.67 vs. today's $3.28.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.02 | $1,623.76 | +62.4% |
| 1 month ago | $2.7 | $1,214.81 | +21.5% |
| 3 months ago | $2.9 | $1,131.03 | +13.1% |
| 6 months ago | $4.49 | $730.51 | -26.9% |
| 1 year ago | $22.67 | $144.68 | -85.5% |
| All time (5.0y) ago | $484.2 | $6.77 | -99.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our TVRD forecast.
Our base-case forecast reaches $6.60 around 2040.
Implied market cap at $6.60: $61.92M
The multi-year forecast points to progressively higher price levels with bullish sentiment sustained into the 2030s and beyond. In 2030, the avg price is projected at $4.35 with a ROI of 32.5% and a bullish stance. By 2040, the avg price rises to $7.44 with a ROI of 126.7% and a bullish stance, followed by 2050 with an avg of $17.34 and a ROI of 428.6%, still labeled bullish.
In earlier years, the forecast shows neutral sentiment, with 2026–2029 expected to produce modest to flat performance (2026 avg $3.28, 2027 $2.98, 2028 $3.29, 2029 $3.21) and corresponding min/max ranges. These are estimates, not guarantees, and reflect the variability of early-stage clinical programs and market conditions.
Tap a question to reveal the answer.
2030 avg price is $4.35 with min $2.69 and max $7.54; ROI 32.5%; sentiment BULLISH.
2031 min $3.43, avg $5.80, max $10.42; ROI 76.8%; sentiment BULLISH.
2040 avg price is $7.44 with min $3.35 and max $16.32; ROI 126.7%; sentiment BULLISH.
2050 avg price is $17.34 with min $7.80 and max $39.88; ROI 428.6%; sentiment BULLISH.
Current price $3.28; Market cap $30.77M; Rank 4764.
Tvardi Therapeutics, Inc. Community Discussion
0Share your Tvardi Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.